NURIX THERAPEUTICS INC(NASDAQ:NRIX) stock News

NRIX Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

a month ago - By: Benzinga

6 Analysts Assess Nurix Therapeutics: What You Need To Know

2 months ago - By: Benzinga - Mentions: BCLI SLRX RDHL SNOA ...

12 Health Care Stocks Moving In Thursday's After-Market Session

3 months ago - By: Nurix Therapeutics, Inc.

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

2 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

3 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström

3 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

3 months ago - By: Yahoo Finance - Mentions: SNY BPMC VZ DHI ...

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

4 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

4 months ago - By: Yahoo Finance - Mentions: DHI CMG

Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now

4 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

4 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

5 months ago - By: Nurix Therapeutics, Inc.

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

5 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

5 months ago - By: Nurix Therapeutics, Inc.

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

5 months ago - By: Zacks Investment Research - Mentions: CUE

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

5 months ago - By: Zacks Investment Research - Mentions: SPRO

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

5 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Nurix Therapeutics, Inc.

NURIX THERAPEUTICS INC (NRIX) Stock News

NRIX Latest News, Press Relases and Analysis

Nurix Therapeutics to Participate in Upcoming Investor Conferences

6 Analysts Assess Nurix Therapeutics: What You Need To Know

12 Health Care Stocks Moving In Thursday's After-Market Session

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors